Literature DB >> 19005479

A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF.

N Bolli1, M F De Marco, M P Martelli, B Bigerna, A Pucciarini, R Rossi, R Mannucci, N Manes, V Pettirossi, S A Pileri, I Nicoletti, B Falini.   

Abstract

In acute myeloid leukaemia (AML), nucleophosmin-1 (NPM1) mutations create a nuclear export signal (NES) motif and disrupt tryptophans at NPM1 C-terminus, leading to nucleophosmin accumulation in leukaemic cell cytoplasm. We investigated how nucleophosmin NES motifs (two physiological and one created by the mutation) regulate traffic and interaction of mutated NPM1, NPM1wt and p14(ARF). Nucleophosmin export into cytoplasm was maximum when the protein contained all three NES motifs, as naturally occurs in NPM1-mutated AML. The two physiological NES motifs mediated NPM1 homo/heterodimerization, influencing subcellular distribution of NPM1wt, mutated NPM1 and p14(ARF) in a 'dose-dependent tug of war' fashion. In transfected cells, excess doses of mutant NPM1 relocated completely NPM1wt (and p14(ARF)) from the nucleoli to the cytoplasm. This distribution pattern was also observed in a proportion of NPM1-mutated AML patients. In transfected cells, excess of NPM1wt (and p14(ARF)) relocated NPM1 mutant from the cytoplasm to the nucleoli. Notably, this distribution pattern was not observed in AML patients where the mutant was consistently cytoplasmic restricted. These findings reinforce the concept that NPM1 mutants are naturally selected for most efficient cytoplasmic export, pointing to this event as critical for leukaemogenesis. Moreover, they provide a rationale basis for designing small molecules acting at the interface between mutated NPM1 and other interacting proteins.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19005479     DOI: 10.1038/leu.2008.326

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  23 in total

1.  Structural polymorphism in the N-terminal oligomerization domain of NPM1.

Authors:  Diana M Mitrea; Christy R Grace; Marija Buljan; Mi-Kyung Yun; Nicholas J Pytel; John Satumba; Amanda Nourse; Cheon-Gil Park; M Madan Babu; Stephen W White; Richard W Kriwacki
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-10       Impact factor: 11.205

2.  Deciphering the folding transition state structure and denatured state properties of nucleophosmin C-terminal domain.

Authors:  Flavio Scaloni; Luca Federici; Maurizio Brunori; Stefano Gianni
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-08       Impact factor: 11.205

Review 3.  A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia.

Authors:  Anuradha Kirtonia; Gouri Pandya; Gautam Sethi; Amit Kumar Pandey; Bhudev C Das; Manoj Garg
Journal:  J Mol Med (Berl)       Date:  2020-07-03       Impact factor: 4.599

4.  The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model.

Authors:  Ke Cheng; Paolo Sportoletti; Keisuke Ito; John G Clohessy; Julie Teruya-Feldstein; Jeffery L Kutok; Pier Paolo Pandolfi
Journal:  Blood       Date:  2009-08-07       Impact factor: 22.113

5.  Expression of the cytoplasmic NPM1 mutant (NPMc+) causes the expansion of hematopoietic cells in zebrafish.

Authors:  Niccolò Bolli; Elspeth M Payne; Clemens Grabher; Jeong-Soo Lee; Adam B Johnston; Brunangelo Falini; John P Kanki; A Thomas Look
Journal:  Blood       Date:  2010-03-02       Impact factor: 22.113

Review 6.  Biological and clinical consequences of NPM1 mutations in AML.

Authors:  E M Heath; S M Chan; M D Minden; T Murphy; L I Shlush; A D Schimmer
Journal:  Leukemia       Date:  2017-01-23       Impact factor: 11.528

7.  α7 helix region of αI domain is crucial for integrin binding to endoplasmic reticulum chaperone gp96: a potential therapeutic target for cancer metastasis.

Authors:  Feng Hong; Bei Liu; Gabriela Chiosis; Daniel T Gewirth; Zihai Li
Journal:  J Biol Chem       Date:  2013-05-13       Impact factor: 5.157

Review 8.  Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications.

Authors:  P Sportoletti; E Varasano; R Rossi; A Mupo; E Tiacci; G Vassiliou; M P Martelli; B Falini
Journal:  Leukemia       Date:  2014-09-02       Impact factor: 11.528

Review 9.  Protein mislocalization: mechanisms, functions and clinical applications in cancer.

Authors:  Xiaohong Wang; Shulin Li
Journal:  Biochim Biophys Acta       Date:  2014-04-04

10.  miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia.

Authors:  Timothy J Molloy; David D Ma; Thi Thanh Vu; Friedrich Stölzel; Kristy W Wang; Christoph Röllig; Melinda L Tursky
Journal:  Leukemia       Date:  2020-12-01       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.